Covishield production in full swing in Pune, says Serum's Adar Poonawalla

Adar Poonawalla, CEO of Serum Institute of India (SII) on Saturday night said that the production of COVID-19 vaccine Covishield is in full swing in Pune.

Covishield
Covishield (Photo: PTI)
ANI Asia
1 min read Last Updated : May 02 2021 | 6:44 AM IST

Adar Poonawalla, CEO of Serum Institute of India (SII) on Saturday night said that the production of COVID-19 vaccine Covishield is in full swing in Pune.

The SII CEO also held a meeting with his partners and stakeholders in the UK.

"Had an excellent meeting with all our partners & stakeholders in the UK. Meanwhile, pleased to state that COVISHIELD's production is in full swing in Pune. I look forward to reviewing operations upon my return in a few days," tweeted Poonawalla.

In a major move, SII had reduced the price of its COVID-19 vaccine 'Covishield' from Rs 400 to Rs 300 per dose for states on Wednesday.

The Ministry of Home Affairs (MHA) on Wednesday also provided Poonawalla with Y category security across the country by the Central Reserve Police Force (CRPF).

Earlier this month, Adar Poonawalla had asked the government for financial assistance to ramp up vaccine production.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: May 02 2021 | 6:39 AM IST

Next Story